ReviewJournal of clinical medicine2025

Time-to-Event Modeling for Survival Prediction of Osimertinib as the First- and Second-Line Therapy.

Sungjae Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.